Literature DB >> 23287570

Recruitment of monocytes/macrophages in different tumor microenvironments.

Heon-Woo Lee1, Hyun-Jung Choi, Sang-Jun Ha, Kyung-Tae Lee, Young-Guen Kwon.   

Abstract

After emigration from the bone marrow into the peripheral blood, monocytes enter tissues and differentiate into macrophages. Monocytes/macrophages have many roles in immune regulation, angiogenesis, and tumor metastasis and invasion. In addition, studies have revealed that these cells are essential to tumor progression. Recently, an accumulation of evidence has indicated that macrophages in distinct regions of tumor masses have distinct origins. For instance, classical monocytes appear to be a major source of macrophages in tumor epithelial, perivascular, and hypoxic regions. In contrast, non-classical monocytes are an important source of macrophages in the tumor perivascular region. During the past century, it has been demonstrated that several chemoattractants can regulate the recruitment of monocytes/macrophages to tumor sites. Despite the importance of monocytes/macrophages in tumor progression, there had been, until recently, no efforts to summarize receptor-ligand pairs between tumor-derived chemokines and corresponding receptors in monocytes in different microenvironments. In this review, we present a cohesive view of the distinct expression patterns of chemokine receptors in two different monocyte subsets (classical and non-classical monocytes) and describe their roles in monocyte/macrophage recruitment into distinct tumor microenvironments. This review provides insight into the behavior of monocytes/macrophages in different tumor microenvironments.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23287570     DOI: 10.1016/j.bbcan.2012.12.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  67 in total

1.  Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment.

Authors:  Trudy Straetemans; Cor Berrevoets; Miriam Coccoris; Elike Treffers-Westerlaken; Rebecca Wijers; David K Cole; Valerie Dardalhon; Andrew K Sewell; Naomi Taylor; Jaap Verweij; Reno Debets
Journal:  Mol Ther       Date:  2014-11-03       Impact factor: 11.454

Review 2.  Immunological Consequences of Epithelial-Mesenchymal Transition in Tumor Progression.

Authors:  Peter J Chockley; Venkateshwar G Keshamouni
Journal:  J Immunol       Date:  2016-08-01       Impact factor: 5.422

3.  Lactoferrin suppresses the Epstein-Barr virus-induced inflammatory response by interfering with pattern recognition of TLR2 and TLR9.

Authors:  Ying Zheng; Zailong Qin; Qiurong Ye; Pan Chen; Zhen Wang; Qun Yan; Zhaohui Luo; Xiaoping Liu; Yanhong Zhou; Wei Xiong; Jian Ma; Guiyuan Li
Journal:  Lab Invest       Date:  2014-07-28       Impact factor: 5.662

4.  Serum CCL2 and CCL3 as potential biomarkers for the diagnosis of oral squamous cell carcinoma.

Authors:  Liang Ding; Bing Li; Ying Zhao; Yi-Fu Fu; Er-Ling Hu; Qin-Gang Hu; Yan-Hong Ni; Ya-Yi Hou
Journal:  Tumour Biol       Date:  2014-07-25

5.  MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth.

Authors:  Junfeng Wang; Fang Yu; Xuemei Jia; Stephen Iwanowycz; Yuzhen Wang; Shiang Huang; Walden Ai; Daping Fan
Journal:  Int J Cancer       Date:  2014-08-30       Impact factor: 7.396

Review 6.  IgE immunotherapy against cancer.

Authors:  Lai Sum Leoh; Tracy R Daniels-Wells; Manuel L Penichet
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

7.  Neutrophil-to-Lymphocyte Ratio After Definitive Concurrent Chemoradiotherapy Predicts Survival in Patients With Esophageal Squamous Cell Carcinoma.

Authors:  Hyeon Kang Koh; Younghee Park; Taeryool Koo; Hae Jin Park; Me Yeon Lee; Ah Ram Chang; Semie Hong; Hoonsik Bae
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

8.  Blood classical monocytes phenotype is not altered in primary non-small cell lung cancer.

Authors:  Saleh A Almatroodi; Christine F McDonald; Allison L Collins; Ian A Darby; Dodie S Pouniotis
Journal:  World J Clin Oncol       Date:  2014-12-10

9.  Anti-VEGFR therapy is one of the healing inhibitors of antiresorptive-related osteonecrosis of the jaw.

Authors:  Chihiro Kanno; Tetsuharu Kaneko; Manabu Endo; Takehiro Kitabatake; Tomoko Sakuma; Yoshiaki Kanaya; Yuki Watanabe; Hiroshi Hasegawa
Journal:  J Bone Miner Metab       Date:  2020-11-16       Impact factor: 2.626

10.  Is cholesterol a mediator of cold-induced cancer?

Authors:  Chandi C Mandal; Ankit Sharma; Mahaveer S Panwar; James A Radosevich
Journal:  Tumour Biol       Date:  2016-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.